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Background: The clinical response to ceftriaxone in patients with typhoid fever is significantly slower than
with ofloxacin, despite infection with Salmonella enterica serovar Typhi (S. Typhi) isolates with similar susceptibil-
ities (MIC 0.03–0.12 mg/L). The response to ofloxacin is slower if the isolate has intermediate susceptibility
(MIC 0.25–1.0 mg/L).
Objectives: To determine the bactericidal activity and post-antibiotic effect (PAE) of ceftriaxone and ofloxacin
against S. Typhi.
Methods: The mean time to reach a 99.9% reduction in log10 count (bactericidal activity) and PAE of ceftriaxone
and ofloxacin were determined for 18 clinical isolates of S. Typhi in time–kill experiments (MIC range for ofloxacin
0.06–1.0 mg/L and for ceftriaxone 0.03–0.12 mg/L).
Results: The mean (SD) bactericidal activity of ofloxacin was 33.1 (15.2) min and 384.4 (60) min for ceftriaxone.
After a 30 min exposure to ofloxacin, the mean (SD) duration of PAE was 154.7 (52.6) min. There was no detect-
able PAE after 1 h of exposure to ceftriaxone. For ofloxacin, bactericidal activity and PAE did not significantly
differ between isolates with full or intermediate susceptibility provided ofloxacin concentrations were main-
tained at 4%MIC.
Conclusions: Infections with S. Typhi with intermediate ofloxacin susceptibility may respond to doses that
maintain ofloxacin concentrations at 4%MIC at the site of infection. The slow bactericidal activity of ceftriaxone
and absent PAE may explain the slow clinical response in typhoid.
Introduction
Typhoid (enteric) fever, caused by Salmonella enterica serovar
Typhi (S. Typhi) and serovar Paratyphi A (S. Paratyphi A), causes
morbidity and mortality in children and young adults in low- and
middle-income countries where adequate sanitation and clean
water are lacking.1 Effective antimicrobial therapy shortens illness
duration and reduces complications and mortality, but resistance
to commonly used agents is widespread.1 A recent systematic re-
view reports a pooled prevalence (95% CI) of fluoroquinolone-
non-susceptible S. Typhi in South Asia between 2015 and 2018 of
70% (38%–94%).2 A large outbreak of ciprofloxacin- and
ceftriaxone-resistant typhoid has affected the Sindh province in
Pakistan since 2016.3 The S. Typhi clade H58 has been particularly
dominant in the spread of these resistant strains across Asia and
some parts of Africa.4
Typhoid fever treatment with ofloxacin results in rapid recov-
ery times and high cure rates even with short treatment
courses, provided the infecting isolates have an MIC 0.1
mg/L.5–9 Infections with isolates with intermediate susceptibil-
ity to ofloxacin, defined by an ofloxacin MIC of 0.25–1.0 mg/L, or
resistance to nalidixic acid or pefloxacin, have prolonged recov-
ery times and increased clinical failure rates.10–12 Ceftriaxone
has an MIC of 0.1 mg/L, in a similar range to susceptible fluoro-
quinolones, but, when used for treatment, the fever recovery
times are slow.5,13–15
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We compared the in vitro bactericidal activities and the
post-antibiotic effects (PAEs) of ofloxacin and ceftriaxone against
clinical isolates of S. Typhi.
Materials and methods
Bacterial strains and patients
The study used 18 unique blood culture isolates of S. Typhi from
Vietnamese patients with uncomplicated typhoid fever before entry into
randomized controlled trials of treatment with short courses of ofloxacin
(OflocetV
R
; Roussel-UCLAF, France) reported previously.6,7 The response to
treatment was assessed by fever clearance time, defined as the time since
treatment began for the temperature to fall below 37.5C and remain at or
below 37.5C for 48 h.
Strains were identified by standard biochemical tests and by agglutin-
ation with specific antisera (Murex, Dartford, UK). Antimicrobial susceptibil-
ity testing against chloramphenicol (30lg), ampicillin (10lg), co-
trimoxazole (1.25/23.75 lg), ceftriaxone (30lg) and nalidixic acid (30 lg)
discs was performed and interpreted using CLSI guidelines.8 The MIC and
MBC of ofloxacin (Roussel-UCLAF, France) and ceftriaxone (RocephinV
R
;
Roche, Hong Kong, China) were determined by the microdilution method
with CAMHB (Difco, MI, USA).
Molecular typing
We determined by modified pyrosequencing if the serovar Typhi strains
were the H58 clade, by inferring genotype though the detection of the
H58-specific SNP and the common SNPs located at positions 83 and 87 in
the gyrA gene and position 80 in the parC that determine intermediate
susceptibility to ofloxacin in the isolates resistant to nalidixic acid.16
Time–kill studies
Ten mL of warm Mueller–Hinton broth containing either ofloxacin (Roussel-
UCLAF, France) or ceftriaxone (RocephinV
R
; Roche, Hong Kong, China) at a
concentration of 8%MIC for the strain used in that experiment was added
at time zero to 10 mL of warm Mueller–Hinton broth containing the isolate
at a bacterial density of approximately 2%106 cfu/mL in log-phase growth
to give a final concentration of drug in the broth of 4%MIC. In the controls,
the added broth contained no drug. The cultures were incubated with shak-
ing at 100 rpm at 35–37C for 24 h. Samples for viable counts were taken
immediately before the addition of the drug or control broth and then at
0.25, 0.5, 1, 2, 4, 6, 9, 12 and 24 h after the addition of drug. Viable counts
were performed in duplicate [see the Supplementary Methods (available as
Supplementary data at JAC Online)]. Each experiment was performed in
triplicate.
PAE
For determination of the PAE, 200lL of broth was removed from each of
the time–kill broths at exactly 30 min (ofloxacin) and 1 h (ceftriaxone) after
the addition of drug and diluted to 1/100 in 20 mL of warm Mueller–Hinton
broth. For the controls, 200 lL of the time–kill control broth was removed
and added to 20 mL of warm Mueller–Hinton broth containing the same
final concentration of antimicrobial agent as in the test PAE tube. Viable
counts were performed immediately after dilution and at hourly intervals
for at least 6 h.
Table 1. Pharmacodynamic parameters for 18 isolates of S. Typhi versus ofloxacin and ceftriaxone [values are the median (range) of three separate
experiments and the mean (SD) for all patient data combined]
Patient code Susceptibility patterna
Ofloxacin
Ceftriaxone
time–kill (min) PAE (min) time–kill (min)
TY65 FS 35 (25–45) 125 (125–215) 320 (155–450)
TY73 FS 25 (25–25) 190 (185–245) 315 (305–450)
TY86 FS 20 (20–20) 240 (85–255) 280 (265–330)
TY98 FS 25 (25–25) 60 (165–165) 475 (192–475)
CT4 FS 35 (35–70) 155 (145–165) 425 (350–435)
CT66 FS 50 (50–50) 110 (30–125) 455 (455–455)
All FS [mean (SD)] 31.7 (10.8) 146.7 (63.2) 378.3 (83.0)
TY77 MDR NAS 25 (25–25) 215 (210–285) 385 (255–475)
TY84 MDR NAS 40 (40–40) 160 (135–185) 440 (415–490)
TY90 MDR NAS 16 (16–16) 200 (135–300) 405 (385–415)
TY97 MDR NAS 35 (21–66) 180 (125–280) 315 (280–330)
CT55 MDR NAS 42 (30–50) 100 (65–190) 415 (395–495)
CT65 MDR NAS 70 (30–100) 100 (50–160) 330 (330–345)
All MDR NAS [mean (SD)] 38.0 (18.5) 159.2 (49.4) 381.7 (49.4)
TY62 MDR NAR 55 (49–55) 110 (85–115) 435 (420–450)
TY169 MDR NAR 45 (20–75) 125 (105–180) 420 (355–445)
CT30 MDR NAR 23 (18–25) 175 (60–190) 425 (420–605)
CT31 MDR NAR 25 (25–25) 105 (25–130) 425 (325–425)
CT75 MDR NAR 10 (10–40) 200 (105–270) 345 (320–450)
CT76 MDR NAR 20 (20–95) 235 (205–235) 310 (300–325)
All MDR NAR [mean (SD)] 29.7 (16.9) 158.3 (53.3) 393.3 (52.4)
aFS, susceptible to chloramphenicol, ampicillin, co-trimoxazole, ceftriaxone and nalidixic acid, and with an ofloxacin MIC 0.12 mg/L; MDR NAS, resistant to
chloramphenicol, ampicillin and co-trimoxazole, but susceptible to ceftriaxone and nalidixic acid, and with an ofloxacin MIC 0.12 mg/L; MDR NAR, resistant











bridge user on 28 July 2021
Determination of bactericidal activity and PAE
Log viable counts were plotted versus time. The bactericidal activity was
the time to reach a 99.9% reduction in log10 count and was calculated by
two people with differences reconciled. The PAE was calculated as the
PAE = T#C, where C is the time for a 1 log10 increase in the viable count
from the moment of dilution of the PAE control and T is the time for a 1
log10 increase from the time of dilution for the test. The mean (SD) for the
bactericidal activity and PAE for each resistance group was compared using
one-way analysis of variance.
Results
MICs and MBCs, haplotype and gyrA mutations
Six isolates were fully susceptible to the drugs tested (FS: suscep-
tible to chloramphenicol, ampicillin, co-trimoxazole, ceftriaxone
and nalidixic acid, and with an ofloxacin MIC0.12 mg/L), six were
MDR NAS (resistant to chloramphenicol, ampicillin and co-
trimoxazole, but susceptible to ceftriaxone and nalidixic acid, and
with an ofloxacin MIC0.12 mg/L) and six were MDR NAR (resistant
to chloramphenicol, ampicillin, co-trimoxazole and nalidixic acid,
but susceptible to ceftriaxone, and with an ofloxacin MIC of
0.25–1.0 mg/L). One MDR NAR strain had an ofloxacin MIC of
0.12 mg/L. The response of patients infected with isolates in each
resistance group to ofloxacin treatment is shown in Table S1 and
Figure S1 (both available as Supplementary data at JAC Online).
The fever clearance time was prolonged (>200 h) for five of the six
patients infected with an MDR NAR isolate; three patients required
rescue antimicrobial treatment, including one patient with a re-
peat positive blood culture who also developed gastrointestinal
bleeding. Six isolates were haplotype H58 and 10 were non-H58. A
single point mutation in the QRDR of the gyrA gene at D87G
(GAC!GGC) was found in four of the MDR NAR isolates and S83F
(TCC!TTC) in one MDR NAR isolate. The remaining MDR NAR isolate
was unavailable for typing.
Time–kill studies and PAE
The mean (SD) bactericidal activity of ofloxacin in the 18 experi-
ments was 33.1 (15.2) min, compared with 384.4 (60) min for
ceftriaxone (Table 1). Typical curves are shown in Figure 1. After
30 min of exposure to ofloxacin, all isolates gave a PAE; mean (SD)
PAE of 157.7 (11.2) min. There were no significant differences for
the time–kill and PAE when comparing the FS, MDR NAS and MDR
NAR isolates exposed to ofloxacin at 4%MIC. There was no detect-
able PAE after 1 h of exposure to ceftriaxone.
Discussion
Ofloxacin at a concentration of 4%MIC was rapidly bactericidal
against susceptible and MDR strains of S. Typhi that had ofloxacin
MICs 0.12 mg/L and those with an MIC of 0.25–1.0 mg/L.
Ofloxacin also provided an average PAE of 158 min against these
organisms. In contrast, ceftriaxone at four times the MIC of
0.12 mg/L demonstrated a slow bactericidal action against all
strains and no PAE.
A pharmacokinetic-pharmacodynamic measure that correlates
with in vivo efficacy of ofloxacin in typhoid is thought to be fCmax/
MIC.17 In Vietnamese children with uncomplicated typhoid fever,
treated with 15 mg/kg/day of oral ofloxacin in two divided doses,
the mean (95% CI) peak serum level was 5.5 (4.7–6.3) mg/L.18
Ofloxacin is approximately 35% bound to plasma proteins, so
this corresponds with an unbound peak level of approximately
3.6 mg/L. In adult healthy volunteers given 200 mg of ofloxacin, a
dose used in a number of the clinical trials, the serum level at 2 h




Figure 1. (a) Time–kill curve for isolate from patient CT65, an MDR NAS
S. Typhi isolate (ofloxacin MIC 0.06 mg/L) exposed to ofloxacin at 4%MIC.
(b) Time–kill curve for isolate from patient TY169, an MDR NAR S. Typhi
isolate (ofloxacin MIC 1.0 mg/L) exposed to ofloxacin at 4%MIC. (c)
Time–kill curve for isolate from patient CT55, an MDR NAS S. Typhi isolate
(ceftriaxone MIC 0.12 mg/L) exposed to ceftriaxone at 4%MIC. This figure
appears in colour in the online version of JAC and in black and white in
the print version of JAC.
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1.3 mg/L.19 For isolates of S. Typhi with an MIC of 0.06 mg/L the
fCmax/MIC ratio will therefore vary between 60:1 and 22:1, well
above the 4%MIC. For isolates with intermediate ofloxacin suscep-
tibility the fCmax/MIC ratio will range between 14.4:1 and 3.6:1 in
children and between 5.2:1 and 1.3:1 in adults. Although isolates
with intermediate susceptibility also demonstrated a PAE, the un-
bound serum level will fall below a value of 4%MIC during the dos-
ing cycle.
Ceftriaxone had a slow bactericidal action against all strains
and no PAE against all the S. Typhi. A pharmacokinetic-
pharmacodynamic target associated with treatment success of
ceftriaxone against other Gram-negative infections is a target at-
tainment of drug levels above the MIC for 100% of the dosing
cycle. The mean (SD) peak serum ceftriaxone level in adolescents
and adults with typhoid in Nepal, treated with 3 g of IV ceftriaxone
once daily, was 291 (92) mg/L and the trough was 21.7 (25.4)
mg/L.20 Even considering that ceftriaxone is 85%–95% protein
bound, the ceftriaxone level is still above the MIC for 100% of the
dosing cycle.
This study has shown that an ofloxacin concentration of 4%MIC
is rapidly bactericidal and has a prolonged PAE in time–kill experi-
ments against S. Typhi isolates with intermediate ofloxacin sus-
ceptibility. In principle, higher doses of ofloxacin than used in these
trials (>15 mg/kg/day) could be clinically effective against such
infections, but may be limited by adverse effects, such as QT
interval prolongation, tendonopathy and cardiac valve disor-
ders. Low-dose regimens of ofloxacin (such as 200 mg twice
daily in adults and 10–15 mg/kg/day in children used in these
trials) risk selecting resistant S. Typhi and are best avoided. In
contrast, ceftriaxone demonstrated slow bactericidal activity
and an absent PAE against S. Typhi and this may contribute to
the slow clinical responses seen with typhoid fever patients
treated with ceftriaxone. With the emergence of isolates resist-
ant to both ceftriaxone and fluoroquinolones the need to
understand the activity of older antimicrobials and to study
new agents against S. Typhi is critical.3
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